IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells

Thyroid carcinomas (TCs) bearing BRAF mutations represent approximately 26 –53% of human thyroid malignancies and, differently from melanomas, are poorly sensitive to BRAF inhibitors (BRAFi), and develop acquired resistance through activation of alternative signaling pathways. A whole-genome gene expression analysis of TC BRAF V600E cells exposed to PLX4032 identified JA K/STAT among the most significantly modulated signaling pathways. Interestingly, both transient exposure and chronic adaptation to PLX4032 resulted in upregulation of IL6/STAT3 axis and this impaired the cytostatic activity of PLX4032.

Source: Cancer Letters - July 2, 2018 Category: Cancer & Oncology Authors: Tiziana Notarangelo, Lorenza Sisinni, Stefania Trino, Giovanni Calice, Vittorio Simeon, Matteo Landriscina Tags: Original Articles Source Type: research